Search Our Scientific Publications & Authors

Cancer Med 2019 Apr 23. Epub 2019 Apr 23.

Nephrology Department, Fundeni Clinical Institute, Bucharest, Romania.

Acute kidney injury (AKI) is a common complication after allogeneic stem cell transplantation; however, its incidence and outcome in patients transplanted for multiple myeloma (MM) is unknown. We evaluated the incidence, severity, and risk factors for AKI within the first 30 days after autologous stem cell transplantation (ASCT) for MM. We prospectively followed 185 consecutive patients with MM, without chronic renal replacement therapy, who underwent ASCT; 12. Read More

J Magn Reson Imaging 2019 Apr 23. Epub 2019 Apr 23.

Mater Misericordiae University Hospital, Dublin, Republic of Ireland.

Technical advances in the last two decades have allowed rapid, high-resolution whole-body magnetic resonance imaging (WBMRI). MRI allows unparalleled visualization and detail in the imaging of bone marrow and surrounding soft tissues. The properties of nuclear magnetic resonance allow superb characterization of bone marrow constituents. Read More

Nat Commun 2019 Apr 23;10(1):1911. Epub 2019 Apr 23.

Department of Hematology and Medical Oncology, Emory University School of Medicine, 1365 Clifton Rd. NE, Atlanta, GA, 30322, USA.

Multiple myeloma is a malignancy of antibody-secreting plasma cells. Most patients benefit from current therapies, however, 20% of patients relapse or die within two years and are deemed high risk. Here we analyze structural variants from 795 newly-diagnosed patients as part of the CoMMpass study. Read More

Blood Adv 2019 Apr;3(8):1318-1329

Division of Translational and Regenerative Medicine, Department of Medicine, The University of Arizona Comprehensive Cancer Center, Tucson, AZ.

Inhibition of bromodomain and extra terminal (BET) protein family members, including BRD4, decreases the expression of c-MYC and other key oncogenic factors and also significantly induces histone deacetylase 6 (HDAC6) expression. On the basis of the role of HDAC6 in malignant pathogenesis, we hypothesized that rational cotargeting of HDAC6 and BET family proteins may represent a novel approach that yields synergistic antimyeloma activity. We used genetic and pharmacologic approaches to selectively impair HDAC6 and BET function and evaluated the consequential impact on myeloma pathogenesis. Read More

Int J Radiat Oncol Biol Phys 2018 Dec;102(5):1602

Crit Rev Oncol Hematol 2019 May 27;137:18-26. Epub 2019 Feb 27.

Department of Medicine, Division of Hematology Oncology, Blood and Marrow Transplantation, University of Arizona, Tucson, AZ, 85721, United States; Taussig Cancer Center, Department of Hematology, Medical Oncology, Cleveland Clinic, Cleveland, OH, 44195, United States. Electronic address:

Multiple Myeloma (MM) is primarily a disease of old age with a median age of sixty-nine years at diagnosis. The development of novel therapies for induction and use of autologous stem cell transplantation has resulted in improved clinical outcomes and better quality of life for MM patients. Elderly patients, comprising the majority of MM population, have a higher incidence of age-related comorbidities, frailty and organ dysfunction which complicates the coordination of treatment and limits the selection of therapies. Read More

Med J Aust 2019 Apr 23. Epub 2019 Apr 23.

Royal Prince Alfred Hospital, Sydney, NSW.

Genetic sequencing of the myeloma genome has not revealed a specific disease-determining genetic alteration. Multiple disease subclones exist at diagnosis and vary in clinical importance with time and drug sensitivity. New diagnostic criteria have identified indications for early introduction of therapy. Read More

Ann Med Surg (Lond) 2019 May 2;41:11-15. Epub 2019 Apr 2.

Department of Orthopaedic and Traumatology Cipto Mangunkusumo General Hospital / Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.

Introduction: To evaluate the response and the correlation between survival and prognostic factors in 32 patients with multiple myeloma.

Method: We recruited 32 patients (18 men and 14 women) with mean age 59 years old who were diagnosed with multiple myeloma that were treated with surgery (n = 21) and without surgery (n = 11). 9 patients underwent hemiarthroplasty, 14 patients underwent open reduction and internal fixation and 4 patients underwent spinal decompression and posterior pedicular instrumentation from January 2012 to December 2017. Read More

Case Rep Oncol 2019 Jan-Apr;12(1):235-240. Epub 2019 Mar 19.

Virginia Tech Carilion School of Medicine, Division of Gastroenterology and Hepatology, Roanoke, Virginia, USA.

Introduction: Metastasis to the gallbladder is not common and usually manifests an advanced stage of malignancy. Herein, we report a case of triple negative high grade invasive ductal carcinoma of breast with a metastatic lesion to the gallbladder.

Case Presentation: The patient is a 52-year-old female diagnosed with invasive ductal carcinoma treated with mastectomy and chemotherapy. Read More

Blood 2019 Apr 22. Epub 2019 Apr 22.

Medical Oncology/Hematologic Malignancies, Dana-Farber Cancer Institute, United States

Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma cell dyscrasia that consistently precedes multiple myeloma (MM) with a 1% risk of progression per year. Recent advances have improved understanding of the complex genetic and immunologic factors that drive and permit progression from aberrant plasma cell clone to MGUS and overt MM. Additional evidence supports a bidirectional interaction of MGUS cells with surrounding cells in the bone marrow niche that regulates malignant transformation. Read More

Blood 2019 Apr 22. Epub 2019 Apr 22.

Hospital Clínic Universitari, IDIBAPS, Barcelona, Spain.

Response criteria for multiple myeloma (MM) require monoclonal protein (M-protein)-negative status on both serum (sIFE) and urine (uIFE) immunofixation-electrophoresis for classification of complete response (CR). However, uIFE is not always performed for sIFE‑negative patients. We analyzed M-protein evaluations from 384 MM patients (excluding those with light-chain-only disease) treated in the GEM2012MENOS65 (NCT01916252) trial in order to determine the uIFE-positive rate in patients who became sIFE-negative post-treatment; and evaluate rates of minimal residual disease (MRD)-negative status and progression-free survival among patients achieving CR, CR but without uIFE available (uncertain CR; uCR), or very good partial response (VGPR). Read More

Cancer Res Treat 2019 Apr 22. Epub 2019 Apr 22.

3Graduate School of Health Science Business Convergence, Chungbuk National University College of Medicine, Cheongju, Korea.

Purpose: This study aimed to determine whether the diagnosis, treatment approach and prognosis of multiple myeloma (MM) vary according to the presence and type of disability.

Materials And Methods: Demographic, socioeconomic, and medical data were obtained from the National Disability Database, the Korean Central Cancer Registry, and the Korean National Health Insurance claims database. An age- and sex-matched cohort was established using a 1:3 ratio constituted with 2,776,450 people with disabilities and 8,329,350 people without disabilities. Read More

Mol Ther Nucleic Acids 2019 Mar 13;16:391-406. Epub 2019 Mar 13.

Department of Precision Medicine, University of Campania "Luigi Vanvitelli," 80138 Naples, Italy; IRGS, Biogem, Molecular and Precision Oncology Laboratory, Via Camporeale, 83031 Ariano Irpino, Italy. Electronic address:

miR-125b, ubiquitously expressed and frequently dysregulated in several tumors, has gained special interest in the field of cancer research, displaying either oncogenic or oncosuppressor potential based on tumor type. We have previously demonstrated its tumor-suppressive role in multiple myeloma (MM), but the analysis of molecular mechanisms needs additional investigation. The purpose of this study was to explore the effects of miR-125b and its chemically modified analogs in modulating cell viability and cancer-associated molecular pathways, also focusing on the functional aspects of stress adaptation (autophagy and senescence), as well as programmed cell death (apoptosis). Read More

J Vis Exp 2019 Apr 6(146). Epub 2019 Apr 6.

Center of Scientific Experiment, Beijing University of Chinese Medicine;

The analysis of the bioactive components present in foods and natural products has become a popular area of study in many fields, including traditional Chinese medicine and food safety/toxicology. Many of the classical analysis techniques require expensive equipment and/or expertise. Notably, enzyme-linked immunosorbent assays (ELISAs) have become an emerging method for the analysis of foods and natural products. Read More

SAGE Open Med Case Rep 2019 10;7:2050313X19838441. Epub 2019 Apr 10.

Division of Foot and Ankle, Henry Ford Health System, Detroit, MI, USA.

We report the case of a 61-year-old man with sharp pain, tender mass at the left lower one-third posterior tibial region. The patient has a 10-year history of multiple myeloma and related chemotherapy. A positron emission tomography computed tomography and magnetic resonance imaging indicated the suspect of a posterior tibial nerve tumor. Read More

Am J Hematol 2019 Apr 21. Epub 2019 Apr 21.

Department of Medicine, Brown University, Warren Alpert Medical School, Providence, RI.

Mol Ther 2019 Apr 8. Epub 2019 Apr 8.

Allogene Therapeutics, Inc., 210 E. Grand Avenue, South San Francisco, CA 94080, USA. Electronic address:

Clinical success of autologous CD19-directed chimeric antigen receptor T cells (CAR Ts) in acute lymphoblastic leukemia and non-Hodgkin lymphoma suggests that CAR Ts may be a promising therapy for hematological malignancies, including multiple myeloma. However, autologous CAR T therapies have limitations that may impact clinical use, including lengthy vein-to-vein time and manufacturing constraints. Allogeneic CAR T (AlloCAR T) therapies may overcome these innate limitations of autologous CAR T therapies. Read More

Blood Rev 2019 Apr 13. Epub 2019 Apr 13.

Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic. Electronic address:

Extramedullary disease of multiple myeloma (EM) remains a treatment challenge even in the era of new drugs. While many reports analyzing various aspects of EM have been published, mechanism of EM development has not been clarified yet. This review summarizes current knowledge about this clinical entity, including its history, diagnostics, imaging methods, incidence, prognosis, current treatment options, risk factors and known molecular mechanisms that might be involved in pathogenesis of EM. Read More

J Clin Lab Anal 2019 Apr 19:e22888. Epub 2019 Apr 19.

Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.

Background: Renal impairment (RI) is a most common complication of multiple myeloma (MM), which is associated with an increased risk of early death and worse survival.

Methods: We retrospectively analyzed clinical features and outcomes of 77 MM patients over 70 years old and compared the differences between with and without RI groups.

Results: The percentage of elder MM patients with RI was 61%. Read More

Haematologica 2019 Apr 19. Epub 2019 Apr 19.

Kameda Medical Center.

Haematologica 2019 Apr 19. Epub 2019 Apr 19.

Dept. of of Hematology, University Medical Center Utrecht Cancer Center, Utrecht, The Netherlands

Blood 2019 Apr 19. Epub 2019 Apr 19.

Jerome Lipper Myeloma Center, Dana Farber Cancer Institute, United States

Aust Dent J 2019 Apr 19. Epub 2019 Apr 19.

Private Practice, Perth, Western Australia, Australia.

Cone beam computed tomography is widely used in dentistry. Incidental findings are common, with many requiring intervention or monitoring. We present a rare case of previously undiagnosed, asymptomatic multiple myeloma first identified incidentally on cone beam computed tomography and panoramic radiography. Read More

Cureus 2019 Feb 4;11(2):e4011. Epub 2019 Feb 4.

Internal Medicine, The University of Arizona, Tucson, USA.

Immunoglobulin (Ig) D multiple myeloma (MM) is a rare subtype of MM comprising 2% of all the cases. Malignant plasma cell invasion leads to signs and symptoms similar to other subtypes of MM. The synthesis rate of IgD is lower in IgD MM patients, making it very difficult to diagnose compared to other subtypes. Read More

Ann Biol Clin (Paris) 2019 Apr;77(2):197-217

IUC-T laboratoire d'hématologie, CHU de Toulouse, Toulouse, France.

Flow cytometric immunophenotyping has become essential for management of multiple myeloma (assessment of clonality, prognostic information on the risk of progression in gammopathy of undetermined significance, minimal residual disease monitoring). Immunophenotyping of bone marrow plasma cells is routinely used in the haematology laboratory of the University Hospital of Toulouse. To guarantee the reliability of this technique, the laboratory decided to check this method in compliance with the NF ISO EN 15189, standard for medical laboratories requirements. Read More

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):489-493

Department of Hematology, Gansu Provincial People＇s Hospital, Lanzhou 730000, Gansu Province, China.

Objective: To study the value of neutrophil/lymphocyte ratio (NLR) in the evaluation of prognosis of patients with multiple myeloma (MM).

Methods: NLR was calculated on the basis of the blood routine examination results of 65 patients with primary MM (MM group) and 83 persons receiving physical examination as control group, and the difference in 2 group was compared; moreover according to the median as threshold, the patients were divided into low NLR group (NLR＜2.34) and high NLR group (NLR≥2. Read More

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):482-488

Department of Orthopedics The Third Affiliated Hospital of Guangzhou University of Tranditional Chinese Medicine;Guangzhou 510000, Guangdong Province, China, E-mail:

Objective: To explore the effect of Bushen Yanggu Decoction (BYD) on drug resistance and proliferation of human multiple myeloma-resistant KM3/BTZ cells.

Methods: Human multidrug-resistant KM3/BTZ cells were established by Bortezomib (BTZ) gradient induction. The effects of commonly used chemotherapeutic drugs and serum containing Bushen Yanggu Decoction (BYD) on the proliferation of KM3 cells and KM3/BTZ cells were detected by MTT assay. Read More

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):477-481

Department of Orthopedics, The Third Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510000, Guangdong Province, China,E-mail:

Objective: To investigate the effecr of siRNA-interfering β-catenin expression on drug-resistance of multiple myeloma cells.

Methods: The multiple myeloma cell line RPMI-8226 was cultured in vitro. The maphalan-resistant cell model was established by concentration gradient ascending of durg, then the drug-resistant cell line was instantaneously transfected with β-catenin siRNA, the sensitivity of RPMI 8226 cells to maphalan was detected by CCK-8 meltod before and after the transfection with siRNA; the mRNA and protein expression of β-catenin was detected by qRT-PCR and Western blot respectively, the apoptosis of cells was detected by flow cytometry. Read More

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):472-476

Department of Hematology, Chaohu Hospital Affiliated to Anhui Medical University，Chaohu 238000, Anhui Province, China.

Objective: To investigate the significance of detecting serum complement C3 and C4 in patients with multiple myeloma (MM) and to explore its correlation with myeloma bone disease (MBD).

Methods: The levels of serum complement C3 and C4 in 69 MM patients and 30 healthy people were examined by scatter nephelometry. The bone density of L1-4 vertebral body, bilateral femoral neck and bilateral hip joints were measured by dual energy bone density meter (DXA). Read More

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):464-471

Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China,E-mail:

Objective: To evaluated the effect of curcumin on the bortezomib-resistant myeloma cells and the expression of Notch1 signaling pathway, in order to further explore its potential mechanism.

Methods: Curcumin, bortezomib, and curcumin combined bortezomib were added into RPMI 8266, U266, 5 nmol/L bortezomib-resistant RPMI 8266 (RPMI 8226-V5R), 5 nmol/L bortezomib-resistant U 266 (U266-V5R) and CD138+ plasma cells respectively. The cell proliferation was measured by MTT assay. Read More

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):458-463

Department of Hematology, Affiliated Hospital, Nanjing University of Traditional Chinese Medicine, Nanjing 210029, Jiangsu Province, China,E-mail:

Objective: To investigate the effects of oridonin (ORI) on the proliferation and apoptosis of human multiple myeloma cell line H929 and its possible mechanism.

Methods: H929 cells were exposed to ORI 0、4、8、12、16、20、24、28、32 μmol/L for 12, 24 and 36 hours respectively. The prolifcration inhibitory effect of ORI on H929 cells was determined by MTT assay and then the working concentrations of ORI were determined. Read More

Clin Case Rep 2019 Apr 22;7(4):699-702. Epub 2019 Feb 22.

Department of Clinical Laboratory Kyoto University Hospital Kyoto Japan.

This report demonstrates that not only heparin-induced thrombocytopenia, but also hemodialysis conditions (platelet activation due to hemodiafiltration and heparin underdosing) may markedly reduce the platelet count and cause clotting in the hemodialysis circuit in patients in a hypercoagulable state. The clot prevention effects of bortezomib are therefore of great importance. Read More

Intern Med 2019 Apr 17. Epub 2019 Apr 17.

Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Japan.

Plasma cell leukemia (PCL) is a rare variant of multiple myeloma. The detection of plasma cells in the peripheral blood and monoclonal protein in the serum or urine is important for the diagnosis of PCL. However, it is sometimes difficult to diagnose PCL in patients with atypical plasma cell morphology and/or those without detectable monoclonal protein. Read More

Drugs R D 2019 Apr 16. Epub 2019 Apr 16.

Department of Hematology, Medical University of Lodz, Ul. Ciolkowskiego 2, 93-510, Lodz, Poland.

Bortezomib is a dipeptidyl boronic acid that selectively inhibits the ubiquitin proteasome pathway, which plays a role in the degradation of many intracellular proteins. It is the first-in-class selective and reversible inhibitor of the 26S proteasome, with antiproliferative and antitumor activity. It exerts its anti-neoplastic action mainly via the inhibition of the nuclear factor-κB pathway components associated with cell proliferation, apoptosis, and angiogenesis. Read More

Leukemia 2019 Apr 16. Epub 2019 Apr 16.

Myeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital-Monash University, Melbourne, VIC, Australia.

Monitoring tumour burden and therapeutic response through analyses of circulating cell-free tumour DNA (ctDNA) and extracellular RNA (exRNA) in multiple myeloma (MM) patients were performed in a Phase Ib trial of 24 relapsed/refractory patients receiving oral azacitidine in combination with lenalidomide and dexamethasone. Mutational characterisation of paired BM and PL samples at study entry identified that patients with a higher number of mutations or a higher mutational fractional abundance in PL had significantly shorter overall survival (OS) (p = 0.005 and p = 0. Read More

Chembiochem 2019 Apr 16. Epub 2019 Apr 16.

University of Birmingham, HWB-NMR, CR UK Institute of Cancer Studies, Vincent Drive, Edgbaston, B15 2TT, Birmingham, UNITED KINGDOM.

Tracer-based metabolism is becoming increasingly important to study metabolic mechanisms in cells. NMR offers several approaches to measure label incorporation in metabolites, including 13C and 1H-detected spectra. The latter are generally more sensitive but quantification depends on the proton carbon 1JCH coupling constant which varies significantly between different metabolites. Read More

Oncology (Williston Park) 2019 04;33(4):149-51, 155

Int J Hematol 2019 Apr 13. Epub 2019 Apr 13.

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.

Autologous stem-cell transplantation is an effective procedure for the treatment of multiple myeloma, and involves the collection of hematopoietic stem cells (HSCs). However, in some patients, HSCs in the bone marrow fail to mobilize. Pomalidomide upregulates CXCR4 in hematopoietic stem cells, in a manner similar to that of lenalidomide, and is, thus, likely to have a negative impact on hematopoietic stem-cell mobilization in multiple myeloma patients. Read More

Exp Ther Med 2019 May 12;17(5):3291-3298. Epub 2019 Mar 12.

Department of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310012, P.R. China.

Triptolide (TPL), an extract of the Chinese herb Hook F, is a potent anti-inflammatory agent that further possesses anticancer activity. Its antiproliferative effects are well established. Only few studies have focused on TPL as a potential treatment in multiple myeloma (MM). Read More

Indian J Hematol Blood Transfus 2019 Apr 21;35(2):215-222. Epub 2018 Jul 21.

Department of Haematology, Christian Medical College, Vellore, 632004 India.

There is paucity of data from developing countries on the clinical outcomes in myeloma post-autologous transplantation. In this retrospective study, we used hospital records to retrieve data of patients with multiple myeloma undergoing autologous stem cell transplantation (ASCT) from January 1995 to December 2014 at our centre. During the study period, 245 patients underwent ASCT for myeloma. Read More

Indian J Hematol Blood Transfus 2019 Apr 13;35(2):205-207. Epub 2019 Mar 13.

2Department of Internal Medicine, PGIMER, Chandigarh, 160012 India.

Bone Marrow Transplant 2019 Apr 15. Epub 2019 Apr 15.

Hematology Department, Complejo Asistencial Universitario de Salamanca-IBSAL, Centro de Investigación del Cáncer-IBMCC, Salamanca, Spain.

Leukemia 2019 Apr 15. Epub 2019 Apr 15.

Division of Hematology, Mayo Clinic, Rochester, MN, 55905, USA.

IL-6 signaling plays a crucial role in the pathogenesis of a number of diseases, including multiple myeloma, primary amyloidosis, cytokine release syndrome and other inflammatory conditions. It is central for the growth and survival of malignant plasma cells. IL-6R and IL-6ST receptors transduce IL-6 signaling. Read More

Proc Natl Acad Sci U S A 2019 Apr 15. Epub 2019 Apr 15.

State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China;

Relapsed and refractory (R/R) multiple myeloma (MM) patients have very poor prognosis. Chimeric antigen receptor modified T (CAR T) cells is an emerging approach in treating hematopoietic malignancies. Here we conducted the clinical trial of a biepitope-targeting CAR T against B cell maturation antigen (BCMA) (LCAR-B38M) in 17 R/R MM cases. Read More

Clin Lymphoma Myeloma Leuk 2019 Mar 8. Epub 2019 Mar 8.

Division of Hematology, Oncology and Stem Cell Transplant, Rush University Medical Center, Chicago, IL. Electronic address:

Kidney Int 2019 Mar 15. Epub 2019 Mar 15.

Department of Nephrology and Renal Transplantation, Centre Hospitalier Universitaire, Université de Poitiers, Poitiers, France; CNRS UMR 7276, INSERM UMR 1262, Université de Limoges, Limoges, France; INSERM CIC 1402, Centre Hospitalier Universitaire, Poitiers, France.

The clinicopathological characteristics of kidney infiltration in B-cell lymphoproliferative disorders remain poorly described. We retrospectively studied 52 adults with biopsy-proven malignant B-cell kidney infiltration, including Waldenström's macroglobulinemia (n=21), chronic lymphocytic leukemia (n=11), diffuse large B-cell lymphoma (DLBCL) (n=8), other lymphoma (n=11), and multiple myeloma (n=1). Kidney disease varied according to the underlying lymphoproliferative disorder. Read More

Cancers (Basel) 2019 Apr 4;11(4). Epub 2019 Apr 4.

Department of Hematology/Oncology, Research Hospital, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.

HDACs are critical regulators of gene expression that function through histone modification. Non-histone proteins and histones are targeted by these proteins and the inhibition of HDACs results in various biological effects. Moreover, the aberrant expression and function of these proteins is thought to be related to the pathogenesis of multiple myeloma (MM) and several inhibitors have been introduced or clinically tested. Read More

Eur J Haematol 2019 Apr 15. Epub 2019 Apr 15.

Henan Institute of Haematology, Department of Hematology, Henan Cancer Hospital, The Affliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.

Multiple myeloma(MM) is still an incurable disease and its pathogenesis involves cytogenetics and epigenetics. In recent years, the roles of long non-coding RNAs (lncRNAs) in MM have been deeply studied by scholars. LncRNAs are defined as a class of nonprotein-coding transcripts greater than 200 nucleotides in length, which are involved in a large spectrum of biological processes, including proliferation, differentiation, apoptosis, invasion and chromatin remodeling. Read More

Cancer 2019 Apr 15. Epub 2019 Apr 15.

Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.

High-dose chemotherapy and autologous stem cell transplantation (ASCT) are a standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (MM). The introduction of novel agents, which range from immunomodulatory drugs and proteasome inhibitors to monoclonal antibodies and have now been integrated into both induction and salvage regimens, has dramatically revolutionized the treatment landscape of MM and challenged the role of high-dose chemotherapy and ASCT in treating MM. These advances have led to a number of provocative questions. Read More